



STATE-OF-THE-ART REVIEW

Druggable genome and precision medicine in cancer: current challenges

Camille Amandine Dupont¹ , Kristina Riegel¹, Malvika Pempaiah¹, Hartmut Juhl^{2,4} and Krishnaraj Rajalingam^{1,3,4} 

1 Cell Biology Unit, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

2 Indivumed GmbH, Hamburg, Germany

3 University Cancer Center Mainz, University Medical Center Mainz, Germany

4 Indivumed-IMCB joint lab, IMCB, A*Star, Singapore

Keywords

biobanking; drug resistance; druggable genome; oncogenes; organoids; personalized therapeutics; precision medicine

Correspondence

K. Rajalingam, Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
E-mail: Krishna@uni-mainz.de

(Received 2 November 2020, revised 10 February 2021, accepted 23 February 2021)

doi:10.1111/febs.15788

The past decades have seen tremendous developments with respect to “specific” therapeutics that target key signaling molecules to conquer cancer. The key advancements with multiomics technologies, especially genomics, have allowed physicians and molecular oncologists to design “tailor-made” solutions to the specific oncogenes that are deregulated in individual patients, a strategy which has turned out to be successful though the patients quickly develop resistance. The swift integration of multidisciplinary approaches has led to the development of “next generation” therapeutics and, with synergistic therapeutic regimes combined with immune checkpoint inhibitors to reactivate the dampened immune response, has provided the much-needed promise for cancer patients. Despite these advances, a large portion of the druggable genome remains understudied, and the role of druggable genome in the immune system needs further attention. Establishment of patient-derived organoid models has fastened the preclinical validation of novel therapeutics for swift clinical translation. We summarized the current advances and challenges and also stress the importance of biobanking and collection of longitudinal data sets with structured clinical information, as well as the critical role these “high content data sets” will play in designing new therapeutic regimes in a tailor-made fashion.

Introduction

The first anticancer drugs available were mainly anti-neoplastic agents, also referred to as cytotoxic compounds, developed based on their ability to kill rapidly dividing cells regardless of their potential mechanism of action. The need for less toxic and cancer cell-selective drugs led to a different drug discovery strategy that

aims to identify inhibitors of cancer-specific molecular targets and test their ability to affect cancer growth in preclinical studies, resulting in “targeted therapies” [1]. Though cytotoxic chemotherapy still plays an important role in cancer treatment, a shift occurred toward the development of targeted agents, driven by advances

Abbreviations

CARs, chimeric antigen receptors; CML, chronic myeloid leukemia; FDA, Food and Drug Agency; GPCR, G protein-coupled receptor; IFN- α 2, interferon- α 2; IL-2, interleukin-2; IMiD, immunomodulatory imide drug; MCSF, macrophage-colony-stimulating factor; NSCLC, non-small-cell lung cancer; PAP, prostate acid phosphatase; PBMCs, peripheral blood mononuclear cells; PD-1, programmed cell death protein 1; PDO, patient-derived organoid; PDX, patient-derived xenograft; PKI, protein kinase inhibitor; PROTAC, proteolysis-targeting chimera; TCRs, T-cell receptors; TGF- β , transforming growth factor- β ; TILs, tumor-infiltrating lymphocytes; Tregs, regulatory T cells.

in genome sequencing techniques and molecular characterization of cancers [2]. The emerging multiplicity of therapeutic options also paved the way toward precision oncology, with an “à la carte” treatment strategy that can be adapted to individual patients.

Here, we will provide an overview of the recent advances brought to cancer treatment by targeted therapies and precision oncology, as well as major challenges that arose with them, such as the inevitable emergence of drug resistance, or the limited predictivity of current pre-clinical models. We will also discuss some of the most promising therapeutic strategies, including immunotherapy and agents promoting target degradation, which bring novel exciting perspectives to the field of oncology.

The druggable genome and the advent of targeted cancer therapy

Therapeutic target discovery has been focused on the druggable genome, as defined by Hopkins and Groom in 2002, that is, the genes and gene products known or predicted to interact with orally bioavailable compounds [3]. Beyond the presence of a protein structure that can be potentially bound by small molecules, good potential targets are proteins for which modulating the biological function might provide therapeutic benefit for the patient. In this perspective, a few protein families have been at the center of attention for cancer drug development, including protein kinases, G protein-coupled receptors (GPCR), and nuclear/hormone receptors [4]. Targeted therapy has proven to be a successful strategy in oncology, with the introduction of novel therapeutic agents, including monoclonal antibodies and small-molecule kinase inhibitors.

Monoclonal antibodies led the way, with rituximab, an anti-CD20 antibody approved for the treatment of low-grade B-cell lymphoma in 1997, followed by a humanized anti-HER2 (ERBB2 receptor tyrosine kinase) monoclonal antibody, trastuzumab, approved in 1998 for the treatment of HER2 overexpressing breast cancer. Overall, 28 monoclonal antibodies have been approved by the US Food and Drug Agency (FDA) for the treatment of various cancer types (Drugs@FDA, data in October 2020, Table S1). Antibody-based therapies also include antibody–drug conjugates, which take advantage of the antibody specificity to deliver cytotoxic drugs to tumor cells, thus minimizing cytotoxicity while enhancing efficacy. The main limit of antibody-based strategies is the large size of antibodies, therefore restricting epitope accessibility to extracellular and membrane-associated targets.

Another classical strategy for targeted therapy is to block protein activity with small-molecule inhibitors.

Notably, protein kinases are highly attractive targets for cancer therapeutics, because they are critical components of intracellular signal transduction pathways involved in various cellular functions deregulated in cancer, such as cell growth, proliferation, differentiation, apoptosis, cell survival, and angiogenesis. A breakthrough for small-molecule protein kinase inhibitors (PKIs) was the approval of imatinib in 2001, developed using rational drug design to target the fusion protein BCR-ABL driving chronic myeloid leukemia (CML). The promising results obtained with imatinib in patients with early-stage CML raised expectations and paved the way for the development of numerous small-molecule kinase inhibitors (Table 1). For extensive reviews on kinase-targeted drug discovery in oncology, see [5–7].

Most PKIs target the kinase domain, especially the first generation which are ATP-competitive inhibitors, classified as type I and type II inhibitors depending on whether they bind the ATP pocket of the kinase in an active or inactive conformation, respectively. These inhibitors require high target binding affinity, because they compete with ATP, which is present in high intracellular levels and binds the ATP pocket with extremely high affinity.

More recently, non-ATP-competitive inhibitors binding kinases outside of the ATP pocket were approved for cancer therapy: mTOR inhibitors temsirolimus and everolimus, in 2007 and 2009; followed by MEK inhibitors trametinib, cobimetinib, binimetinib, and selumetinib from 2013 to 2020. These allosteric inhibitors are generally more specific than ATP-competitive inhibitors, as they target protein domains bearing less homology within the kinases than the ATP pocket, resulting in less off-target effects [8]. In the last decade, covalent inhibitors have also reached the clinics, starting with the approval in 2013 of the BTK inhibitor ibrutinib; and of afatinib, which targets EGFR, HER2, HER4, and some EGFR mutants resistant to first-generation EGFR inhibitors. This newer generation of small-molecule kinase inhibitors binds to their target with covalent bonds, resulting in higher potency, prolonged pharmacodynamics, and fewer off-target effects [9]. The development of these last-generation small-molecule inhibitors was the result of research efforts for solving major issues in cancer therapy: target specificity and drug resistance.

Multitargeting therapy approaches to combat drug resistance

A major and everlasting challenge in oncology is the acquired pharmacological resistance resulting from the selective pressure created by any drug treatment,

Table 1. List of FDA-approved Protein Kinase Inhibitors for cancer treatment ([60] as of October 2020)

Protein kinase inhibitor	Approval year	Indications	Primary targets
Abemaciclib	2017	Breast cancer	CDK4/6
Acalabrutinib	2017	Lymphoma	BTK
Afatinib	2013	Lung cancer	EGFR; ERBB2; ERBB4
Alectinib	2015	Lung cancer	ALK; RET
Avapritinib	2020	Gastrointestinal cancer	PDGFR; KIT
Axitinib	2012	Kidney cancer	VEGFR
Binimetinib	2018	Melanoma	MEK1/2
Bosutinib	2012	Leukemia	BCR-ABL
Brigatinib	2017	Lung cancer	ALK; EGFR
Cabozantinib	2012	Thyroid cancer; kidney cancer; hepatocellular carcinoma	VEGFR2; MET; RET
Capmatinib hydrochloride	2020	Lung cancer	MET
Ceritinib	2014	Lung cancer	ALK
Cobimetinib	2015	Melanoma	MEK1/2
Crizotinib	2011	Lung cancer	ALK; MET
Dabrafenib	2013	Melanoma; lung cancer; thyroid cancer	BRAF
Dacomitinib	2018	Lung cancer	EGFR
Dasatinib	2006	Leukemia	BCR-ABL
Encorafenib	2018	Melanoma; colorectal cancer	BRAF
Entrectinib	2019	Lung cancer; solid tumors	TRKA/B/C; ROS1
Erdafitinib	2019	Urothelial carcinoma	FGFR
Erlotinib hydrochloride	2004	Pancreatic cancer; lung cancer	EGFR
Everolimus	2009	Breast cancer; kidney cancer; neuroendocrine tumors	mTOR
Fedratinib	2019	Myelofibrosis	JAK2
Gefitinib	2003	Lung cancer	EGFR
Gilteritinib	2018	Leukemia	FLT3
Ibrutinib	2013	Lymphoma	BTK
Imatinib mesylate	2001	Leukemia; gastrointestinal cancer	BCR-ABL; KIT; PDGFR
Lapatinib ditosylate	2007	Breast cancer	EGFR; ERBB2
Larotrectinib	2018	Solid tumors	TRKA/B/C
Lenvatinib	2015	Thyroid cancer; kidney cancer; hepatocellular carcinoma; endometrial carcinoma	VEGFR; FGFR; PDGFRA; RET; KIT
Lorlatinib	2018	Lung cancer	ALK

Table 1. (Continued).

Protein kinase inhibitor	Approval year	Indications	Primary targets
Midostaurin	2017	Leukemia	FLT3
Neratinib	2017	Breast cancer	ERBB2
Nilotinib	2007	Leukemia	BCR-ABL
Osimertinib	2015	Lung cancer	EGFR T790M
Palbociclib	2015	Breast cancer	CDK4/6
Pazopanib hydrochloride	2009	Kidney cancer; soft tissue sarcoma	VEGFR; PDGFRA/B; KIT
Pemigatinib	2020	Cholangiocarcinoma	FGFR
Pexidartinib	2019	Tenosynovial giant cell tumor	CSF1R; KIT; FLT3
Ponatinib hydrochloride	2012	Leukemia	BCR-ABL
Pralsetinib	2020	Lung cancer	RET
Regorafenib	2012	Colorectal cancer; gastrointestinal cancer; hepatocellular carcinoma	VEGFR; RET; KIT; PDGFRA/B; FGFR1/2; RAF1; BRAF
Ribociclib	2017	Breast cancer	CDK4/6
Ripretinib	2020	Gastrointestinal cancer	KIT; PDGFRA
Ruxolitinib phosphate	2011	Myeloproliferative disorder	JAK1/2
Selpercatinib	2020	Lung cancer; thyroid cancer	RET
Selumetinib sulfate	2020	Neurofibroma	MEK1/2
Sorafenib tosylate	2005	Kidney cancer; hepatocellular carcinoma; thyroid cancer	BRAF; RAF1; VEGFR; PDGFRB; KIT; FLT3; RET
Sunitinib malate	2006	Gastrointestinal cancer; kidney cancer; pancreatic cancer	VEGFR; FLT3; RET; KIT; PDGFRA/B; CSF1R
Temsirolimus	2007	Kidney cancer	mTOR
Trametinib	2013	Melanoma; lung cancer; thyroid cancer	MEK1/2
Tucatinib	2020	Breast cancer	ERBB2
Vandetanib	2011	Thyroid cancer	EGFR; VEGFR2
Vemurafenib	2011	Melanoma; histiocytic sarcoma	BRAF
Zanubrutinib	2019	Lymphoma	BTK

whether they are kinase inhibitors or antibody-based therapies. Two types of resistance can be encountered: primary or intrinsic resistance, when the tumor does not respond to treatment; and secondary or acquired resistance, which occurs after an initial response to treatment and involves the selection of resistant cancer cells.

Resistance to protein kinase inhibitors might be due to mutation of key residues in the catalytic domain (e.g. gatekeeper residue), preventing compound binding to the target, or rewiring of the signaling network. One notorious example is imatinib: the initial enthusiasm for imatinib has been quickly dampened by the occurrence of cancer relapse caused by the emergence of drug resistance. The molecular causes of resistance to imatinib include mutations in the catalytic domain of ABL tyrosine kinase, thus impairing imatinib binding, or the activation of alternative signaling pathways, such as increased activation of Src family kinases [10]. Several alternative BCR-ABL inhibitors have since been developed, trying to overcome resistance to imatinib in CML: dasatinib, nilotinib, bosutinib, and ponatinib, which targets also the gatekeeper mutation T315I resistant to all other BCR-ABL inhibitors [11].

Developing selective small-molecule kinase inhibitors is challenging, due to the high conservation of sequence and structure shared among the ATP-binding pockets of kinases. Indeed, numerous FDA-approved kinase inhibitors target multiple kinases [7]. The resulting lack of target specificity of these kinase inhibitors can lead to toxicity and side effects due to off-target inhibition. However, polypharmacological properties of drugs can sometimes be turned into a therapeutic advantage, for instance by targeting several kinases involved in cancer pathogenicity and progression with a single inhibitor [10]. Evidence suggests that it might not be sufficient to block one specific kinase to achieve a clinical benefit, whereas multitargeted kinase inhibitors might be more promising in terms of therapeutic potency, and for preventing drug resistance [12].

One of the first multikinase inhibitor approved in oncology was sorafenib. Initially designed as a RAF inhibitor, sorafenib also targets several other receptor tyrosine kinases (VEGFR, PDGFR, c-Kit, and RET) [13]. This large range of cellular targets involved in tumorigenesis led to the approval of sorafenib for the treatment of several malignancies: advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid cancer resistant to radioactive iodine treatment. The targeting of VEGFR and PDGFR also limits angiogenesis, thus countering tumor development on multiple fronts. Several other multikinase inhibitors were then approved for cancer treatment, for which inhibition of secondary targets contributes to their effectiveness. For example, imatinib primarily targets BCR-ABL in CML, but the identification of its additional targets c-KIT and PDGFR extended its use as first-line therapy of c-KIT-positive gastrointestinal stromal tumors [7]. The discovery of novel targets for well-established

anticancer drugs stresses the importance of rigorously investigating their molecular mechanism of action, in order to allow a rational use and combination of these drugs that could provide a better patient outcome.

Combinatorial treatments

An alternative to multitargeted kinase inhibitors is the combination of small-molecule kinase inhibitors with classical chemotherapy or with other targeted agents. Two strategies can be employed here: vertical pathway inhibition, targeting several effectors in the same signaling pathway; or horizontal inhibition, to prevent the overactivation of another pathway in response to target inhibition. One example of vertical pathway inhibition is the combination of the BRAF and MEK inhibitors, vemurafenib and cobimetinib, approved in 2015 for the treatment of advanced BRAF-mutated melanoma [14], although the success of this strategy is limited by the emergence of drug resistance. The horizontal inhibition strategy is still in its infancy and is currently being tested in clinical trials (e.g., BRAF or MEK inhibitor combined to PI3K inhibitor). However, there is so far no approved combination of two kinase inhibitors targeting different signaling pathways, mostly due to dose-limiting toxicity [15]. Horizontal pathway inhibition has nevertheless been successful, for example by combining the small-molecule PI3K α inhibitor alpelisib to fulvestrant, an estrogen receptor antagonist, a combination approved in 2019 for some subtypes of breast cancer [16]. Additionally, the synergistic action of the HDAC inhibitor chidamide with EGFR inhibitors is being explored, with promising preclinical data for the treatment of non-small-cell lung cancer (NSCLC) raising high hopes for this strategy [17].

In the development of synergistic treatment regimes, a rational combination of drugs targeting multiple hallmarks of cancer is of greatest importance (Fig. 1). As described by Hanahan and Weinberg, there are 10 hallmarks of cancer ranging from “sustained proliferative signaling” to “avoiding immune destruction” [18]. Thus, combining therapies which increase tumor immunogenicity and reverse tumor immunosuppression have the benefit of killing the tumor cells while simultaneously promoting the activation of the immune system [19]. Another example of successful drug combinations is anti-angiogenesis agents such as the VEGF inhibitor bevacizumab, which was the first to be approved by the FDA in combination with an intravenous 5-fluorouracil-based chemotherapy regimen [20]. With a view to develop new combinatorial treatment strategies, other nononcology drugs that have the

potential to target cancer hallmarks and the related cancer biology might be considered as well. As only recently summarized by Zhang *et al.*, there are multiple candidates, like metformin or indomethacin, that were originally approved for other indications but could also be considered for cancer treatment [21]. Metformin is an approved diabetes drug that has been shown to lower the risk of breast cancer in women with type 2 diabetes [22]. Another meta-analysis revealed a positive correlation between metformin and the overall survival of lung cancer patients [23]. In addition, an improved response to radiotherapy of patients with prostate cancer was demonstrated [24]. The underlying mechanism contributing to the anticancer activity of metformin is the negative regulation of mTOR, which is involved in tumor survival [25]. Moreover, it has been demonstrated that metformin inhibits the secretory phenotype of senescent cells thus functioning as a senostatic [26]. Recently, senostatics as well as senolytics, which are drugs selectively killing senescent cells, are suggested to be beneficial as a secondary therapy after DNA-damaging therapies [27–29]. The rational reason behind this is that although therapy-induced senescence contributes to inhibition of tumor growth, it also opens up the possibility of relapse due to a resistant population. Tumor cells escaping from therapy-induced senescence have then the potential to be more tumorigenic and metastatic [30,31]. In addition, increased senescence in normal tissues due to DNA-damaging therapies is associated with long-term functional impairment, which is clinically expressed as an age-like phenotype. The administration of senostatics or senolytics could also compensate for this, which could in turn have a positive effect on the health of long-term cancer survivors [27].

The design of polypharmacological drugs and therapeutic combination strategy relies on a deep understanding of the pharmacology of each agent. Consistency and reliability of information on drug–target interaction, including secondary target or “off-target” information, are of utmost importance [32]. For this purpose, several online resources gathering detailed drug–target annotations have been developed, such as DrugBank [33] (www.drugbank.ca), DrugCentral [34] (drugcentral.org), the Drug Gene Interaction Database (DGIdb) [35] (dgidb.org), or the ProteomicsDB database [36] (www.proteomicsdb.org). It is also crucial to precisely identify the signaling pathways driving a particular tumor type, and the key effectors to simultaneously target for achieving synergistic antitumor effects [37]. Furthermore, the combinatorial strategy is facing the challenge to achieve a good balance between survival gain and toxicity.

Overall, rational drug combinations require a systematic investigation of the biological consequences of drug treatments, and the evaluation of the pharmacology of the agent beyond its primary mode of action.

Druggable targets in the immune system

Although targeted therapeutics surprised by their profound clinical response in genetically defined patient populations, fast-developing drug resistance limited the excitement since clinical responses were often not durable. Therefore, other strategies have also been pursued to expand the repertoire of possible cancer therapies. A reasonable approach was the development of immunotherapeutics that support the antitumor immune response.

An efficient immune response depends on the complex interplay of a variety of signals and interactions, and on the functionality of different immune cells [38]. However, cancer cells can adopt various immune suppressive mechanisms that lead to reduced immunogenicity and evasion of immune surveillance. Suppression of the antitumor immune response can be hereby mediated through the loss of target antigen expression [39], the recruitment of regulatory T cells (Tregs) [40], modulated dendritic cells (DCs), alternatively activated M2 macrophages [41], and myeloid-derived suppressor cells (MDSCs) [42]. Together with the cancer cells, these immune cells contribute to the creation of a suppressive tumor microenvironment by secreting inhibitory cytokines and expression of checkpoint inhibitors so that the functionality of tumor-reactive effector T cells (Teffs) is dampened [43,44]. Main strategies of immunotherapeutics to alleviate tumor immune evasion include immune checkpoint blockade, cytokine therapy, and cellular therapy [43,44].

An immune suppressive tumor microenvironment is established through cytokines such as transforming growth factor- β (TGF- β) [45] and also through metabolites such as kynurenine. Consequently, several studies on how immunosuppressive factors could be targeted in the tumor microenvironment are being conducted to develop therapeutic strategies that support antitumor immune responses [46]. Among the targets that are evaluated for therapeutic purposes are the aforementioned TGF- β [47], the indoleamine 2,3-dioxygenase (IDO) family [48] which catabolizes tryptophan to kynurenine, the macrophage-colony-stimulating factor (M-CSF) [49], and the vascular endothelial growth factor A (VEGFA), or their receptors [50]. Besides targeting immunosuppressive factors, the




Fig. 1. Targeting the hallmarks of cancer. Figure modified from [123]. Also indicated are representative drugs that target various hallmarks of cancer.

administration of pro-inflammatory cytokines to patients can potentially support the antitumor immune response by activating key immune effectors. In 1986, recombinant interferon $\alpha 2$ (IFN- $\alpha 2$) was the first human immunotherapeutic approved by the FDA for cancer and has since then been clinically assessed as monotherapy or in combination [51]. Today IFN- $\alpha 2$ plays a rather subordinate clinical role since the effectiveness was exceeded by some other therapeutics [51]. Aldesleukin, a recombinant form of interleukin-2 (IL-2), represents another immunotherapeutic that was approved by the FDA for metastatic melanoma and renal cell cancer [52]. However, due to its severe toxicity and its tendency to amplify Tregs, IL-2 cannot be used widely for cancer therapy. Consequently, new strategies involving the generation of IL-2 mutants with varying binding affinities to the IL-2 receptor and of tumor-targeting IL-2 are now being developed to improve the efficacy, while reducing the toxicity of IL-2 [52,53].

Another meaningful cancer treatment strategy is the adoptive transfer of *ex vivo* expanded tumor-infiltrating lymphocytes (TILs) and of T cells engineered with chimeric antigen receptors (CARs) or recombinant T-cell receptors (TCRs) [54]. As recently reviewed by Wolf *et al.*, clinical trials that investigated the effectiveness of TIL therapy focused mainly on patients with metastatic melanoma [55]. However, more and more clinical trials are now also conducted for the treatment of other cancers such as non-small-cell lung cancer (e.g., NCT03215810) or ovarian cancer (e.g., NCT04072263). Due to the good response rate and the largely manageable treatment-related toxicities, the new focus is now to optimize TIL production, to include selection of T-cell subsets, to coordinate the therapy with lymphodepletion and IL-2 application, and to expand the TIL therapy to combination therapy and other solid tumors [56]. Clinical trials evaluating the efficiency of TCR T cells have recruited patients with melanoma, colorectal cancer, advanced

multiple myeloma, and acute myeloid leukemia, among others [55]. So far, TCRs against melanoma-associated antigen (MAGE)-A3 and New York esophageal squamous cell carcinoma (NY-ESO)-1 demonstrated high response rates with rare durable and complete responses [55,57,58]. Due to a higher risk of autoreactivity and associated toxicities, a careful selection of targets is clearly required during the clinical development [55]. The benefit of CARs is that the MHC-independent antigen recognition enables them to recognize any molecule present on the surface of the tumor cells, and they recognize larger epitopes which reduce the risk of cross-reactivity [59]. The FDA has approved two anti-CD19 CAR T-cell products in 2017 [55] and another one in 2020 [60] for the treatment of patients with certain types of B-cell malignancies. However, solid tumors remain a challenge for CAR therapy due to the need of identifying specific tumor antigens [55].

Alternatively, T-cell-mediated killing of cancer cells can be induced through therapeutic cancer vaccines. This approach is used, for example, by the FDA-approved therapy with Sipuleucel-T in prostate cancer. Here, a fusion protein of the prostatic acid phosphatase (PAP) and granulocyte-M-CSF (GM-CSF) serves as a vaccine, which is incubated with autologous peripheral blood mononuclear cells (PBMCs). Due to GM-CSF, antigen-presenting cells within the PBMCs are activated, and after the infusion of the PBMCs into the patients, they are capable of inducing the replication of PAP-specific immune T cells that kill PAP-positive prostate cancer cells [61].

An immense breakthrough in the development of cancer therapeutics was achieved through immune checkpoint inhibitors that interfere with inhibitory signaling pathways of the immune system and enable tumor-reactive T cells to overcome regulatory mechanisms. The first FDA-approved immune checkpoint inhibitor, the monoclonal antibody ipilimumab, targets cytotoxic T lymphocyte antigen-4 (CTLA-4) and has been initially approved in 2011 for the treatment of metastatic melanoma. In addition, combination therapy with ipilimumab and the immune checkpoint inhibitor nivolumab, which targets the programmed cell death protein 1 (PD-1), has been proven to be beneficial and is now approved for the treatment of metastatic melanoma regardless of BRAF mutation status, advanced renal cell carcinoma and metastatic NSCLC [62]. Especially, the immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are considered very successful, as demonstrated by their wide area of application. For instance, the anti-PD-1 antibody pembrolizumab is, as summarized by Wei *et al.*, approved for the treatment of a multitude of cancers including

metastatic melanoma, NSCLC, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, and unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors [62]. The landscape survey of Xin Yu *et al.* further emphasizes how strongly the field of PD-1/PD-L1 inhibitors is growing [63]. Between September 2017 and September 2019 alone, the FDA has approved 23 new indications for PD-1/PD-L1 monoclonal antibodies. Also, the list of clinical studies is expanding with more than 3000 clinical trials launched since 2006 [63]. Despite the success of immune checkpoint inhibitors that lead to long-term durable responses, only a fraction of the patients benefit from them. In addition, as reviewed by Draghi *et al.*, tumor-intrinsic and tumor-extrinsic mechanisms are described that can lead to tumor resistance and to disease progression after an initial response [64].

Further progress in the development of successful treatment regimens was achieved after understanding that the tumor microenvironment has a major impact on drug efficacy. This provided the rationale for combination therapies with immune checkpoint inhibitors, which have become the backbone of cancer therapy [46]. As already extensively reviewed, immune checkpoint inhibitors are currently being combined with numerous therapies and clinically tested to determine whether the tumors respond better to treatment [19,46,65,66]. Once again, toxicity might be an issue, and the synergistic benefits could be limited to a subset of patients [67]. As we discuss below, there are also other strategies besides combination therapies being explored involving the new therapeutic tools and biomarker-guided therapies [64].

Targeting the “undruggable” genome using novel therapeutics

Drug design and efforts toward the discovery of novel inhibitors

Two decades after the advent of targeted cancer therapy, a large portion of the druggable genome remains to be explored. Some research programs aim to highlight understudied areas of the druggable genome, such as the Illuminating the Druggable Genome initiative launched by the US National Institutes of Health in 2014. They resulted in a list of understudied protein kinases, GPCRs, and ion channels that can serve as novel targets in drug discovery [68]. Worth noting is the small fraction of protein kinases that are currently targeted by FDA-approved agents [69]. To this date, the FDA approved 62 small-molecule PKI, including

55 indicated for cancer treatment (Table 1), which target only about 40 different kinases [70], while the human genome encodes more than 500 kinases.

Additionally, some major oncogenic drivers such as RAS, MYC, STAT3, Hippo/YAP, or PAX3-FOXO remain “undruggable” in cancer, despite decades of research. Considerable efforts are deployed to develop novel generations of small-molecule inhibitors targeting “undruggable” proteins. One striking example is the recent discovery of KRAS^{G12C}-specific inhibitors. The RAS small GTPases have long been a conundrum for drug design, due to the lack of a druggable pocket besides the GTP-binding pocket, bound by its natural ligand with extremely high affinity. In the KRAS^{G12C} mutant, the cysteine residue was recognized as an opportunity for drug design by targeting it with covalent inhibitors, which led to the development of covalent KRAS^{G12C} small-molecule inhibitors. In August 2018, AMG 510 (sotorasib) was the first to enter clinical testing for treatment of NSCLC, closely followed by MRTX849 (adagrasib) in January 2019. Another future perspective is the structure-based design of allosteric kinase inhibitors, which bind outside the ATP-binding site in druggable pockets potentially important for modulating the enzymatic activity, for example, through changes in the kinase conformation or inhibition of effector binding [71–73]. One example is asciminib, a type IV allosteric BCR-ABL inhibitor currently in clinical trials for refractory CML. Its selective binding to the ABL myristoyl pocket induces a shift toward inactive kinase conformation [74]. Such strategies could enable the rational development of allosteric inhibitors with better target specificity while overcoming the limitations of active site occupancy.

The rise of targeted proteolysis with PROTACs

Rather than inhibiting enzymatic activity or effector binding, an alternative promising strategy is to induce the degradation of disease-related proteins using proteolysis-targeting chimeras (PROTACs). PROTACs are bifunctional molecules that possess a small-molecule binder, or warhead, which specifically targets the protein of interest and is chemically linked to an E3-ubiquitin ligase recruiting moiety. The induced proximity between the target and the E3-ubiquitin ligase leads to polyubiquitination of the protein of interest and its degradation by the proteasome. Several different strategies have been pursued to recruit ubiquitin ligases, including a VHL (von Hippel–Lindau) peptide ligand to recruit the ubiquitin ligase CRL2^{VHL}, a ligand of the ubiquitin ligase MDM2, or IAP (inhibitors of apoptosis protein) ligand modules. Many

more options can still be explored for drug development using PROTACs, since there are more than 600 E3 ligases with different activity profiles and tissue distribution patterns [75].

More recently, the targeted proteolysis strategy immensely benefited from the discovery of the “molecular glue” properties of the immunomodulatory imide drug (IMiD) thalidomide, and its derivatives lenalidomide and pomalidomide. Thalidomide received FDA approval for the treatment of multiple myeloma in 1998, and IMiDs are now widely used for the treatment of hematological malignancies. But only recently has the molecular mechanism underlying their anti-angiogenic and antineoplastic activity been unraveled, leading to a most exciting avenue for drug development. Cereblon (CRBN) was identified as the primary direct target of IMiDs responsible for their anticancer activity [76]. Binding of IMiDs to CRBN leads to recognition of neosubstrates by the CRBN-containing E3 ubiquitin ligase complex CRL4^{CRBN}, and their subsequent ubiquitination and degradation via the ubiquitin proteasome system.

PROTACs present significant advantages compared to conventional small-molecule inhibitors [75,77]. First, this strategy can be applied to proteins classically considered as “undruggable targets” and scaffolding proteins, since PROTACs binding to their target is not restricted to the catalytic domain but can rather be through lower affinity and/or allosteric binding. Indeed, one PROTAC molecule can be “reused”, thus reducing the number of drug molecules needed to achieve a given efficacy, a characteristic that could also have the benefit of reducing off-target effects. Additionally, since PROTACs induce proteolysis of the target, they are expected to present prolonged effects compared to classical inhibitors, and they could presumably limit the emergence of resistance mechanisms via paradoxical activation of signaling pathways. The design of PROTAC degraders requires careful assessment of cell permeability, target engagement through the formation of ternary complex, target ubiquitination, and target-specific degradation [78]. One particular challenge is that minor modifications in the linker position and length can strongly affect target selection and degradation in an unforeseeable way [75].

The first PROTACs to enter clinical trials were the degraders of androgen receptor ARV-110 and of estrogen receptor ARV-471, currently in phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov Identifier: NCT03888612) and of ER+/HER2- locally advanced or metastatic breast cancer (NCT04072952), respectively. PROTAC design is a prolific field, with the extensive

development of degraders targeting proteins relevant for cancer therapy, such as BRD4, BCL-X_L, BCR-ABL, or ALK [79]. Ongoing progress with other notoriously “undruggable” targets such as RAS [80] or STAT3 [81] gives hopes of expanding the druggable genome.

In the future, more PROTAC degraders and other targeted proteolysis therapeutics are expected to enter clinical development, which raises high expectations for the inhibition of “undruggable” targets.

Bringing novel therapeutics to the clinics

Despite the immense research efforts in drug discovery, only a few novel therapeutics are approved. This is in part due to the need to more accurately determine the driver mutations in a specific tumor, which is to be achieved by identifying new therapeutic targets through large-scale tumor-profiling projects. The failure of novel drugs in clinical trials can also be attributed to the limited predictivity of preclinical models in terms of efficacy, toxicity, and drug resistance, which must be weighed against the ever-increasing costs of drug development and clinical trials.

Identification of novel drug targets through tumor-profiling projects

A large number of tumors lack known and established driver mutations, which sometimes makes it challenging to distinguish amongst passenger mutations in tumors with high mutation burden. Many tools are now available, from genomics to *in silico* modeling, to analyze tumors and identify novel druggable targets.

Cost reductions in next-generation sequencing technologies enabled systematic large-scale cancer genome sequencing projects, such as The Cancer Genome Atlas [82], and the Sanger Cancer Genome Project, later integrated into the International Cancer Genome Consortium [83]. These comprehensive genomic, epigenomic, and transcriptomic databases allow the research community to discover novel cancer-associated genetic aberrations, including noncoding mutations, oncogenic gene fusions, copy-number variants, and drug resistance mutations. Emergent complementary approaches include proteomic, phosphoproteomic, and metabolomic analysis of tumors to precisely assess protein levels, enzymatic activity, and post-translational modifications. They constitute helpful resources to characterize tumor biomarkers, activated oncogenic kinases, novel fusion proteins, or cancer-specific neoantigens for immunotherapeutics [84,85].

These large-scale tumor-profiling data sets are therefore a precious tool for discovering clinically relevant biomarkers and for stratification of tumor subtypes. They also provide the invaluable opportunity to expand the cancer targetome by identifying novel “actionable” mutations (Fig. 2).

Tumor biobanks to fulfill the need for high-quality patient material

Transcriptomic, proteomic, and metabolomic analyses of tumor samples require high-quality material from pathology after surgery. Recent studies have inferred a role for postoperative ischemia (Cold Ischemia timings) that affects the activation of oncogenic pathways, thus impacting diagnosis [86,87]. However, high-quality tumor tissue samples from patients are often not available for research once they have served their primary diagnostic purpose. This is due to multiple limitations, from insufficient size of the surgical sample to inadequate sample storage after surgery and the lack of proper patient consent. Often these standard operating procedures are not standardized and accompanied with the collection of critical clinical data points. The comprehensive collection of clinical data sets with follow-up data is pertinent to make informed clinical decisions on therapy design and management. A solution might be the constitution of comprehensive biobanks of high-quality cancer samples for research use obtained from referral centers, with standardized collection procedures [88,89]. Establishing such biobanks requires a close collaboration between research facilities and participating hospitals. Availability of high-quality tumor samples will be essential for research progress in understanding tumor mechanisms, analyzing enzymatic activity and activation of signaling pathway, as well as for discovery and validation of novel biomarkers for clinical use [90]. Integration of multi-omics data sets with structured clinical information with artificial intelligence-assisted tools will be the norm very soon in treating cancer patients (Fig. 2) [91].

Improving preclinical models for an accurate validation of novel therapeutics

Efficient preclinical models that maintain the tumor heterogeneity and microenvironment are essential for understanding cancer biology, disease development, drug efficacy, and response to treatments. Development of such models is a challenging errand. The majority of research is performed on patient-derived cancer cells cultured as two-dimensional (2D)




Fig. 2. Overview of precision oncology: From the patient to the development of novel therapeutics. Shown in the illustration is the pipeline that starts with the collection of biological materials from patients for multiomics analysis, to drug development, validation, and clinical outreach.

monolayers and maintained in an *in vitro* setting. Cancer cell lines are quick to establish, cost-effective, and amenable to multiple experimental procedures including high-throughput drug screens. However, the establishment of these cell lines requires phenotypic and genetic adaptation, and over time they acquire an undefined mutational background different from the original tumor. Moreover, cancer cell lines do not represent the cellular heterogeneity and architecture found in the original tissue [92,93].

Alternative and better models, such as animal models and patient-derived xenografts (PDX), can maintain tumor heterogeneity and interactions between stroma, vasculature, and immune components. PDXs are generated by direct implantation of human tumor tissue into immunocompromised mice. They have been used for biomarker identification and preclinical drug testing [94]. These models are compelling, but their establishment is time- and resource-consuming, very inefficient, and varies among tumors. In addition,

limited scalability makes high-throughput analysis inefficient and expensive [95–97].

Organoid models in cancer precision medicine

The development of patient-derived organoid (PDO) culture systems provided a unique platform for personalized medicine. Three-dimensional structures termed “organoids” are generated from self-organizing stem cells that mimic key features and functionality of the original tissue. Organoids have unlimited expansion capacity, they are genetically stable, can be cryopreserved, and are amenable to many techniques including genetic manipulation (reviewed in [98]). Organoids can be developed from embryonic stem cells, induced pluripotent stem cells, or tissue-resident adult stem cells. Adult stem cell-derived organoids can be derived from both healthy and tumor tissue [99].

To study cancer, organoids have been employed in two different ways; first healthy epithelial organoids

have been genetically modified to unravel the roles of specific mutations in tumorigenesis. In colon healthy organoids, the consecutive introduction of the most commonly mutated colorectal cancer genes *APC*, *TP53*, *KRAS*, and *SMAD4* gave rise to colorectal cancer organoids with characteristics of invasive carcinoma upon xenotransplantation into immunodeficient mice. Also, results showed that the loss of *APC* and *TP53* causes chromosome instability and aneuploidy, which are considered the initial hallmarks of cancer [100,101]. The second approach is the establishment of living biobanks constituted of patient-derived organoids from tumor and matched adjacent healthy tissue. Such biobanks have been generated for lung [102], breast [103], colorectum [104,105], colon [106], ovary [107,108], prostate [109], pancreas [110–112], esophagus [113], liver [114,115], and metastatic gastrointestinal cancers [116]. The organoids in these biobanks recapitulate the broad histopathological and molecular spectrum of the parental tumor and in many studies, engrafting PDOs into immunodeficient mice confirmed *in vitro* observations. Therefore, they provide a powerful platform to study and understand cancer, and useful tools for drug screening that facilitate the development of new drugs.

Colon organoid biobanks generated from cancer tissue and adjacent healthy tissue were sequenced to reveal all subtypes of colon carcinoma, showing that organoid culture is not restricted to specific subtypes. As a proof of principle, 83 approved drugs were screened using the biobank organoids and the results correlated with the known drug sensitivity based on known mutations [105,106]. Another study showed evidence that drug response measured in PDOs correlates to clinical outcomes. In this study, organoid lines were derived from metastatic gastrointestinal cancer patients who were enrolled in phase I to III clinical trials. The same drugs used in the clinical trials were also tested on PDOs whose responses mimicked the ones of the patients [116]. In the case of pancreatic cancer, Tiriace *et al.* tested chemotherapeutic agents in PDOs, with the specificity of PDO response reflected in the individual treatment response of the patient, including a longitudinal case study for an individual patient [117]. The identification of new therapeutic targets was described using liver tumor PDOs, out of 29 agents tested on PDOs, the ERK inhibitor SCH772984 was identified as a potentially effective agent for all subtypes of primary liver carcinoma. The efficacy was validated *in vivo* using xenotransplanted PDOs in mice [114]. Similar success was achieved in prostate cancer: 306 substances were tested in a high-throughput drug screen revealing the selective potency of the BCL-2

inhibitor, navitoclax, which is being tested in clinical trials of castration-resistant prostate cancer [118]. These are some examples confirming that PDOs can serve as useful preclinical models to assist precision medicine.

Unfortunately, organoid technology does not come without limitations. First, compared to standard 2D cultures, the costs associated with this system are very high and organoids are labor-intensive. Moreover, the success rate in generating tumor organoids varies greatly depending on the tumor type, with the added complication that healthy cells overgrow the others. Second, for high-throughput drug screening and validation, automation is essential. Third, tumor organoids are purely epithelial and have no blood vessels, stroma, immune, or nerve cells, which makes it impossible to study the influence of these cell types on the tumor. This problem is currently countered by coculture methods with immune cells, lymphocytes, and the use of air–liquid interface systems [102,119,120]. In conclusion, PDOs have demonstrated their potential for both modeling cancer and drug screening for personalized medicine. It is expected that the scope and clinical impact of PDOs as a powerful tool will increase in the future.

The input of precision medicine to oncology

Over the last two decades, the advent of targeted cancer therapy has been accompanied by a shift toward precision oncology [121]. Precision oncology signifies the rational adaptation of a therapeutic strategy to individual patient-specific tumor biology and genetics. Indeed, extensive tumor profiling is essential for identifying reliable genetic biomarkers and actionable targets.

Before anything else, precision diagnostic is primordial to achieve patient-tailored treatment [91–93][122]. It is fundamental to determine the subpopulation of patients who would benefit from a given therapy, by identifying specific biomarkers that would help to predict the response to a treatment as well as the occurrence of adverse effects due to genetic predisposition.

With the implementation of precision oncology, the design of clinical trials has been adapted, resulting in two types of clinical trials based on precision diagnostics [121]. The so-called umbrella trials comprise multiple treatment arms, and patients with a given tumor type are assigned to different arms depending on tumor genetic alterations identified in each patient by genomic sequencing. Each patient therefore receives a therapy that specifically targets the driver mutation

identified in their tumor. Another complementary approach is the basket trials, in which patients are assigned treatments that are specific to oncogenic driver aberration, regardless of the cancer type.

Precision oncology also includes a close monitoring of the disease to assess the tumor's response to treatment and possible adaptations of therapeutic interventions in case of suspected drug resistance. Molecular testing can also serve after the start of the treatment to evaluate the occurrence of resistance mutation. The analysis of circulating tumor cell cDNA in plasma also represents a valuable advance as it provides a noninvasive method for monitoring the disease burden.

Combining the advances of precision diagnostics in oncology together with the newest targeted therapy strategies might be the path to improved cancer treatment.

Concluding remarks

The advancement in genomics has enabled to design patient-specific therapies including cancer vaccines, which have not been discussed here, and clinical trials are already ongoing. Personalized therapeutics have gained momentum but the challenge remains in the collection, storage, processing of high-quality biomaterials, and collection of structured clinical information with longitudinal data sets. Acquiring patient follow-up data has logistics issues including consenting and sharing of sensitive data for analytical platforms within and outside the institutions. AI-assisted tools give the hope to digest enormous information to provide the options and snapshot of the underlying tumor drivers, for the tumor boards to make informed decisions. Yet, the druggable genome needs further attention and novel drugs are needed to cater to the unmet medical need in treating advanced cancers and drug resistance. While synergistic therapeutic regimes including immune modulators are becoming a norm, the role of the druggable genome in the immune system needs in-depth characterization. The availability of public large-scale data sets has enormously helped cancer researchers, and in the future, the inclusion of data from different ethnicities will remain a key for a global outreach. Repurposing of drugs will be crucial, which will also cut the costs toward clinical development, further accelerating the approval process and clinical translation. Tumor boards across the hospitals are thankfully getting multidisciplinary, and experts already make their attempts to “understand” each other in the best interests of the patients, still waiting in the wards for the new hope.

Acknowledgements

We thank the members of the KR laboratory and Indivumed-IMCB Joint laboratory for discussions. KR's laboratory is supported by grants from CRC 1292, TP05, EKFS (SUNMAPK), and Deutsche Krebs Hilfe (DKH 70113042) and Forschungszentrum für Immuntherapie of the University Medical Center Mainz to KR. We thank Dr. Daniela Hoeller for critical reading of the manuscript. KR was supported through a Heisenberg professorship of the DFG (RA1739/4-1) and a GFK fellowship.

Conflict of interest

KR is a scientific advisory board member of Indivumed, and Prof. Hartmut Juhl is the CEO of Indivumed group.

Author contributions

CAD, KR, MP, HJ, and KR contributed to the concept, design, writing, and editing of the manuscript. CAD served as the lead and further prepared the figures with MP.

References

- Winkler GC, Barle EL, Galati G & Kluwe WM (2014) Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. *Regul Toxicol Pharmacol* **70**, 46–53.
- Sun J, Wei Q, Zhou Y, Wang J, Liu Q & Xu H (2017) A systematic analysis of FDA-approved anticancer drugs. *BMC Syst Biol* **11**, 87.
- Hopkins AL & Groom CR (2002) The druggable genome. *Nat Rev Drug Discov* **1**, 727–730.
- Kinch MS (2014) An analysis of FDA-approved drugs for oncology. *Drug Discov Today* **19**, 1831–1835.
- Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP & Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. *Mol Cancer* **17**, 48.
- Kannaiyan R & Mahadevan D (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. *Expert Rev Anticancer Ther* **18**, 1249–1270.
- Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R & Sounni NE (2020) Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. *Cancers (Basel)* **12**, 1–17.
- Panicker RC, Chattopadhyaya S, Coyne AG & Srinivasan R (2019) Allosteric small-molecule serine/

- threonine kinase inhibitors. *Adv Exp Med Biol* **1163**, 253–278.
- 9 Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH & Gray NS (2013) Developing irreversible inhibitors of the protein kinase cysteinome. *Chem Biol* **20**, 146–159.
 - 10 Petrelli A & Giordano S (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. *Curr Med Chem* **15**, 422–432.
 - 11 Daub H, Specht K & Ullrich A (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. *Nat Rev Drug Discov* **3**, 1001–1010.
 - 12 Gentile C, Martorana A, Lauria A & Bonsignore R (2017) Kinase inhibitors in multitargeted cancer therapy. *Curr Med Chem* **24**, 1671–1686.
 - 13 Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R & Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nat Rev Drug Discov* **5**, 835–844.
 - 14 Eroglu Z & Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. *Ther Adv Med Oncol* **8**, 48–56.
 - 15 Tolcher AW, Peng W & Calvo E (2018) Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. *Mol Cancer Ther* **17**, 3–16.
 - 16 Copur MS (2020) Alpelisib to treat breast cancer. *Drugs Today* **56**, 357–363.
 - 17 Zhang N, Liang C, Song W, Tao D, Yao J, Wang S, Ma L, Shi Y & Han X (2019) Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC. *J Cancer* **10**, 1275–1287.
 - 18 Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* **144**, 646–674.
 - 19 Joshi S & Durden DL (2019) Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. *J Oncol* **2019**, 5245034.
 - 20 Meadows KL & Hurwitz HI (2012) Anti-VEGF therapies in the clinic. *Cold Spring Harbor Perspect Med* **2**, a006577
 - 21 Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y & Huang C (2020) Overcoming cancer therapeutic bottleneck by drug repurposing. *Signal Transd Target Therapy* **5**, 113.
 - 22 Gallagher EJ & LeRoith D (2015) Obesity and diabetes: The increased risk of cancer and cancer-related mortality. *Physiol Rev* **95**, 727–748.
 - 23 Zhong S, Wu Y, Yan X, Tang J & Zhao J (2017) Metformin use and survival of lung cancer patients: meta-analysis findings. *Indian J Cancer* **54**, 63–67.
 - 24 Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamara P, Milosevic M *et al.* (2013) Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. *Clin Cancer Res* **19**, 6741–6750.
 - 25 Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ & Manning BD (2017) Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. *Cell Metab* **25**, 463–471.
 - 26 Moiseeva O, Deschênes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN & Ferbeyre G (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. *Aging Cell* **12**, 489–498.
 - 27 Short S, Fielder E, Miwa S & von Zglinicki T (2019) Senolytics and senostatics as adjuvant tumour therapy. *EBioMedicine* **41**, 683–692.
 - 28 Sieben CJ, Sturmlechner I, van de Sluis B & van Deursen JM (2018) Two-step senescence-focused cancer therapies. *Trends Cell Biol* **28**, 723–737.
 - 29 Myrianthopoulos V, Evangelou K, Vasileiou PVS, Cooks T, Vassilakopoulos TP, Pangalis GA, Kouloukoussa M, Kittas C, Georgakilas AG & Gorgoulis VG (2019) Senescence and senotherapeutics: a new field in cancer therapy. *Pharmacol Therap* **193**, 31–49.
 - 30 Milanovic M, Yu Y & Schmitt CA (2018) The senescence-stemness alliance – a cancer-hijacked regeneration principle. *Trends Cell Biol* **28**, 1049–1061.
 - 31 Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA *et al.* (2018) Senescence-associated reprogramming promotes cancer stemness. *Nature* **553**, 96–100.
 - 32 Blucher AS, Choonoo G, Kulesz-Martin M, Wu G & McWeeney SK (2017) Evidence-based precision oncology with the cancer targetome. *Trends Pharmacol Sci* **38**, 1085–1099.
 - 33 Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z *et al.* (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* **46**, D1074–D1082.
 - 34 Ursu O, Holmes J, Knockel J, Bologa CG, Yang JJ, Mathias SL, Nelson SJ & Oprea TI (2017) DrugCentral: online drug compendium. *Nucleic Acids Res* **45**, D932–D939.

- 35 Cotto KC, Wagner AH, Feng Y-Y, Kiwala S, Coffman AC, Spies G, Wollam A, Spies NC, Griffith OL & Griffith M (2018) DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. *Nucleic Acids Res* **46**, D1068–D1073.
- 36 Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, Reinecke M, Ruprecht B, Petzoldt S, Meng C *et al.* (2017) The target landscape of clinical kinase drugs. *Science* **358**, eaan4368.
- 37 Rao S, Du G, Hafner M, Subramanian K, Sorger PK & Gray NS (2019) A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. *J Biol Chem* **294**, 8664–8673.
- 38 Chen DS & Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. *Immunity* **39**, 1–10.
- 39 Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ & Lotze MT (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. *J Clin Invest* **98**, 1633–1641.
- 40 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M *et al.* (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* **10**, 942–949.
- 41 Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichter T, Decker WK, Whelan RL, Kumara HMCS *et al.* (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol* **35** (Suppl), S185–S198.
- 42 Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP & Lin PC (2004) Expansion of myeloid immune suppressor Gr⁺CD11b⁺ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell* **6**, 409–421.
- 43 Andersen MH (2019) Anti-cancer immunotherapy: breakthroughs and future strategies. *Semin Immunopathol* **41**, 1–3.
- 44 Christofi T, Baritaki S, Falzone L, Libra M & Zaravinos A (2019) Current perspectives in cancer immunotherapy. *Cancers (Basel)* **11**, 1–38.
- 45 Pasche B (2001) Role of transforming growth factor beta in cancer. *J Cell Physiol* **186**, 153–168.
- 46 Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quarantino S, Sabatos-Peyton C, Petruzzelli L *et al.* (2017) Prospects for combining targeted and conventional cancer therapy with immunotherapy. *Nat Rev Cancer* **17**, 286–301.
- 47 Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA & Lawrence DP (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. *PLoS One* **9**, e90353.
- 48 Spranger S, Koblish HK, Horton B, Scherle PA, Newton R & Gajewski TF (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. *J Immunother Cancer* **2**, 3.
- 49 Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC & Joyce JA (2016) The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. *Science* **352**, aad3018.
- 50 Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N *et al.* (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. *Cancer Immunol Res* **2**, 632–642.
- 51 Borden EC (2019) Interferons α and β in cancer: therapeutic opportunities from new insights. *Nat Rev Drug Discov* **18**, 219–234.
- 52 Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, Mahmoud MM, Warsi MK, Rasool M & Jamal MS (2018) Prospects of IL-2 in cancer immunotherapy. *Biomed Res Int* **2018**, 9056173.
- 53 Sun Z, Ren Z, Yang K, Liu Z, Cao S, Deng S, Xu L, Liang Y, Guo J, Bian Y *et al.* (2019) A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8⁺ T-cell response and effective tumor control. *Nat Commun* **10**, 3874.
- 54 Rosenberg SA & Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* **348**, 62–68.
- 55 Wolf B, Zimmermann S, Arber C, Irving M, Trueb L & Coukos G (2019) Safety and tolerability of adoptive cell therapy in cancer. *Drug Saf* **42**, 315–334.
- 56 Rohaan MW, van den Berg JH, Kvistborg P & Haanen JBAG (2018) Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. *J Immunother Cancer* **6**, 102.
- 57 Lu Y-C, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA *et al.* (2017) Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. *J Clin Oncol* **35**, 3322–3329.
- 58 Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Golubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J *et al.* (2015) NY-ESO-1-specific TCR-engineered T cells mediate

- sustained antigen-specific antitumor effects in myeloma. *Nat Med* **21**, 914–921.
- 59 Casucci M, Hawkins RE, Dotti G & Bondanza A (2015) Overcoming the toxicity hurdles of genetically targeted T cells. *Cancer Immunol Immunother* **64**, 123–130.
 - 60 www.fda.gov. (2020) FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. FDA.
 - 61 Cheever MA & Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. *Clin Cancer Res* **17**, 3520–3526.
 - 62 Wei SC, Duffy CR & Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov* **8**, 1069–1086.
 - 63 Xin YuJ, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM & Tang J (2020) Trends in clinical development for PD-1/PD-L1 inhibitors. *Nat Rev Drug Discov* **19**, 163–164.
 - 64 Draghi A, Chamberlain CA, Furness A & Donia M (2019) Acquired resistance to cancer immunotherapy. *Semin Immunopathol* **41**, 31–40.
 - 65 Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N & Miller WH (2020) A review of cancer immunotherapy: from the past, to the present, to the future. *Curr Oncol* **27**, S87–S97.
 - 66 Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H *et al.* (2019) Advances in cancer immunotherapy 2019 - latest trends. *J Exp Clin Cancer Res* **38**, 268.
 - 67 Naderi-Azad S & Sullivan R (2020) The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. *Expert Rev Anticancer Ther* **20**, 131–136.
 - 68 Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J *et al.* (2018) Unexplored therapeutic opportunities in the human genome. *Nat Rev Drug Discov* **17**, 317–332.
 - 69 Li YH, Wang PP, Li XX, Yu CY, Yang H, Zhou J, Xue WW, Tan J & Zhu F (2016) The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective. *PLoS One* **11**, e0165737.
 - 70 Roskoski R (2020) Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. *Pharmacol Res* **152**, 104609.
 - 71 Nicola G, Kufareva I, Ilatovskiy AV & Abagyan R (2020) Druggable exosites of the human kinome. *J Comput Aided Mol Des* **34**, 219–230.
 - 72 Lu X, Smaill JB & Ding K (2019) New promise and opportunities for allosteric kinase inhibitors. *Angew Chem Int Ed Engl*.
 - 73 Cheng S-S, Yang G-J, Wang W, Leung C-H & Ma D-L (2020) The design and development of covalent protein-protein interaction inhibitors for cancer treatment. *J Hematol Oncol* **13**, 26.
 - 74 Schoepfer J, Jahnke W, Berellini G, Buonomici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T *et al.* (2018) Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. *J Med Chem* **61**, 8120–8135.
 - 75 Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G & Zhou D (2020) PROTeolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. *Oncogene* **39**, 4909–4924.
 - 76 Ito T & Handa H (2020) Molecular mechanisms of thalidomide and its derivatives. *Proc Jpn Acad, Ser B* **96**, 189–203.
 - 77 Li X & Song Y (2020) Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. *J Hematol Oncol* **13**, 50.
 - 78 Verma R, Mohl D & Deshaies RJ (2020) Harnessing the power of proteolysis for targeted protein inactivation. *Mol Cell* **77**, 446–460.
 - 79 Barghout SH (2020) Targeted protein degradation: an emerging therapeutic strategy in cancer. *Anticancer Agents Med Chem*.
 - 80 Zeng M, Xiong Y, Safaei N, Nowak RP, Donovan KA, Yuan CJ, Nabat B, Gero TW, Feru F, Li L *et al.* (2020) Exploring targeted degradation strategy for oncogenic KRASG12C. *Cell Chem Biol* **27**, 19–31.e6.
 - 81 Zhou H, Bai L, Xu R, Zhao Y, Chen J, McEachern D, Chinnaswamy K, Wen B, Dai L, Kumar P *et al.* (2019) Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein. *J Med Chem* **62**, 11280–11300.
 - 82 Tomczak K, Czerwińska P & Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemp Oncol (Pozn)* **19**, A68–77.
 - 83 Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, Liang Y, Rivkin E, Wang J, Whitty B *et al.* (2011) International cancer genome consortium data portal—a one-stop shop for cancer genomics data. *Database (Oxford)* **2011**, bar026.
 - 84 Tayanloo-Beik A, Sarvari M, Payab M, Gilany K, Alavi-Moghadam S, Gholami M, Goodarzi P, Larijani B & Arjmand B (2020) OMICS insights into cancer histology; metabolomics and proteomics approach. *Clin Biochem* **84**, 13–20.
 - 85 Macklin A, Khan S & Kislinger T (2020) Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. *Clin Proteomics* **17**, 17.
 - 86 Aktas B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, Jiang T, Ononye SN, Wali VB, Pusztai L *et al.*

- (2014) Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. *Mol Oncol* **8**, 717–727.
- 87 Guerrera F, Tabbò F, Bessone L, Maletta F, Gaudiano M, Ercole E, Annaratone L, Todaro M, Boita M, Filosso PL *et al.* (2016) The influence of tissue ischemia time on RNA integrity and Patient-Derived Xenografts (PDX) engraftment rate in a Non-Small Cell Lung Cancer (NSCLC) biobank. *PLoS One* **11**, e0145100.
 - 88 Devereux L, Watson PH, Mes-Masson A-M, Luna-Crespo F, Thomas G, Pitman H, Speirs V, Hall AG, Bollinger N, Posada M *et al.* (2019) A review of international biobanks and networks: success factors and key benchmarks—a 10-year retrospective review. *Biopreserv Biobank* **17**, 512–519.
 - 89 Patil S, Majumdar B, Awan KH, Sarode GS, Sarode SC, Gadgil AR & Gondivkar S (2018) Cancer oriented biobanks: a comprehensive review. *Oncol Rev* **12**, 357.
 - 90 Lommen K, Odeh S, de Theije CC & Smits KM (2020) Biobanking in molecular biomarker research for the early detection of cancer. *Cancers (Basel)* **12**, 1–11.
 - 91 Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho C-M *et al.* (2020) Enabling technologies for personalized and precision medicine. *Trends Biotechnol* **38**, 497–518.
 - 92 Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W *et al.* (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* **9**, 391–403.
 - 93 Stein WD, Litman T, Fojo T & Bates SE (2004) A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. *Cancer Res* **64**, 2805–2816.
 - 94 Cho S-Y (2020) Patient-derived xenografts as compatible models for precision oncology. *Lab Anim Res* **36**, 14.
 - 95 DuPage M & Jacks T (2013) Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. *Curr Opin Immunol* **25**, 192–199.
 - 96 Giovanella BC, Yim SO, Stehlin JS & Williams LJ (1972) Development of invasive tumors in the “nude” mouse after injection of cultured human melanoma cells. *J Natl Cancer Inst* **48**, 1531–1533.
 - 97 Rygaard J & Povlsen CO (1969) Heterotransplantation of a human malignant tumour to “Nude” mice. *Acta Pathol Microbiol Scand* **77**, 758–760.
 - 98 Clevers H (2016) Modeling development and disease with organoids. *Cell* **165**, 1586–1597.
 - 99 Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ *et al.* (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* **459**, 262–265.
 - 100 Drost J, van Jaarsveld RH, Ponsioen B, Zimmerlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H *et al.* (2015) Sequential cancer mutations in cultured human intestinal stem cells. *Nature* **521**, 43–47.
 - 101 Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T & Sato T (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat Med* **21**, 256–262.
 - 102 Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K & Ramos E. (2019) Long-term expanding human airway organoids for disease modeling. *EMBO J* **38**, 1–20.
 - 103 Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H *et al.* (2018) A living biobank of breast cancer organoids captures disease heterogeneity. *Cell* **172**, 373–386.e10.
 - 104 Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CGM, van der Velden DL, Peeper DS, Cuppen EPJG *et al.* (2015) Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proc Natl Acad Sci USA* **112**, 13308–13311.
 - 105 Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, Ohta Y, Toshimitsu K, Nakazato Y, Kawasaki K *et al.* (2016) A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. *Cell Stem Cell* **18**, 827–838.
 - 106 van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L *et al.* (2015) Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell* **161**, 933–945.
 - 107 Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H *et al.* (2018) Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. *Cancer Discov* **8**, 1404–1421.
 - 108 Kopper O, de Witte CJ, Löhmußaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J,

- Proost N, Begthel H *et al.* (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. *Nat Med* **25**, 838–849.
- 109 Gao D, Vela I, Sboner A, Iaquinia PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK *et al.* (2014) Organoid cultures derived from patients with advanced prostate cancer. *Cell* **159**, 176–187.
 - 110 Boj SF, Hwang C-I, Baker LA, Chio IIC, Engle DD, Corbo V, Jager M, Ponz-Sarvisé M, Tiriach H, Spector MS *et al.* (2015) Organoid models of human and mouse ductal pancreatic cancer. *Cell* **160**, 324–338.
 - 111 Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K *et al.* (2018) Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. *Cell Stem Cell* **22**, 454–467.e6.
 - 112 Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, Miller DK, Christ AN, Bruxner TJC, Quinn MC *et al.* (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* **531**, 47–52.
 - 113 Sato T, Stange DE, Ferrante M, Vries RGJ, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD *et al.* (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* **141**, 1762–1772.
 - 114 Broutier L, Mastrogiorganni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP *et al.* (2017) Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. *Nat Med* **23**, 1424–1435.
 - 115 Hu H, Gehart H, Artegiani B, López-Iglesias C, Dekkers F, Basak O, van Es J, Chuva de Sousa Lopes SM, Begthel H, Korving J *et al.* (2018) Long-term expansion of functional mouse and human hepatocytes as 3D organoids. *Cell* **175**, 1591–1606.e19.
 - 116 Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R *et al.* (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science* **359**, 920–926.
 - 117 Tiriach H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhardt RA, Denroche RE, Jang G-H *et al.* (2018) Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. *Cancer Discov* **8**, 1112–1129.
 - 118 Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K *et al.* (2017) Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. *Eur Urol* **71**, 319–327.
 - 119 Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S *et al.* (2018) Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. *Cell* **174**, 1586–1598.e12.
 - 120 Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou S-H, Salahudeen AA, Smith AR *et al.* (2018) Organoid modeling of the tumor immune microenvironment. *Cell* **175**, 1972–1988.e16.
 - 121 Doroshow DB & Doroshow JH (2020) Genomics and the history of precision oncology. *Surg Oncol Clin N Am* **29**, 35–49.
 - 122 Brown NA & Elenitoba-Johnson KSJ (2020) Enabling precision oncology through precision diagnostics. *Annu Rev Pathol* **15**, 97–121.
 - 123 Baker S, Ali I, Silins I, Pyysalo S, Guo Y, Högborg J, Stenius U & Korhonen A (2017) Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer. *Bioinformatics* **33**, 3973–3981.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. List of FDA-approved molecular entities and therapeutic biological products for cancer treatment ([60] as of October 2020).